We are collected here on an extremely foggy night to deal with a subject which is to many of us a very foggy one.
Dr. Tocantins: The first speaker will be Dr. Sidney Farber, Professor of Pathology at the Harvard Medical School.
Dr. Sidney Farber (Boston):
In making these introductory remarks I would like to recall that it is less than fourteen years since the temporary control of cancer in man was produced by the use of a chemical agent, thus giving realization to the hope that achievements in the chemical control of infectious disease might be paralleled in cancer. The last few years have witnessed temporary chemical control, characterized by improvement in health, often complete clinical remission, and increase in survival of patients with lymphoma, Hodgkin's disease, and both acute and chronic leukemias. For many of these great advances we are indebted to our British colleagues, many of them working in association with Professor Haddow at the Chester Beatty Institute.
Under the term chemotherapy we will include alkylating agents such as the nitrogen mustards, antimetabolites such as folic acid and purine antagonists, a group of antibiotics and hormones, hormone analogues, and cortical steroids, and finally viruses, which I would choose to regard as chemical agents when they are effective against cancer, and bacterial products such as the bacterial polysaccharides. A wide variety of disseminated tumours in man, impossible to cure by other methods, has shown response to some of these agents, which have also been of value initially in the treatment of lymphoma and leukemia.
What of the future? Solution of the problems of acquired resistance and of toxicity would increase greatly the effectiveness of those agents at present in use, and might well convert temporary control into permanent cure. A new era of combined radiotherapy and chemotherapy has been opened. The possibility of treating radio-resistant forms of chronic leukxemia, lymphoma, or Hodgkin's disease by chemical potentiation of radiotherapy is being studied. This study was initiated because of the profound effect of radiotherapy on some hitherto radio-insensitive tumours, such as the rhabdomyosarcoma, when combined with treatment with agents such as Actinomycin D. Rational approaches to the synthesis of new chemical anti-cancer agents have been created, either by basic research or by knowledge acquired concerning the mechanism of action of carcinolytic agents of proved value. Most programmes are concerned with the synthesis of additional alkylating agents, or with the search for new antimetabolites, antienzymes or nucleic acid inhibitors.
These achievements of chemotherapy of cancer in man have led in the United States to the inauguration by Congressional action of the largest voluntary co-operative medical research programme ever attempted in peacetime. This programme, administered by the National Cancer Institute in Bethesda, unites the several private organizations and the branches of the Government with interests in this field, and includes communication with investigators in all countries. Greatly increased support to individual investigators, groups and institutions has been made available for basic as well as applied research. In addition, large co-operative programmes in the several areas of importance such as organic synthesis, screening, methodology, pharmacology, biochemistry, endocrinology, and clinical investigation have made possible rapid expansion in all areas. Of great importance is the largescale participation of industry in this programme Individual sensitivity to the administration of cancerocidal agents is not confined to neoplastic tissue. There is a rather wide scatter in the amount of these drugs that patients can tolerate before bringing about serious depression of the bone-marrow and consequent cytopenias in the peripheral blood. All too often the enthusiastic chemotherapist will destroy the patient along with the malignant disease by virtue of an empty bone-marrow.
It is of extreme importance, then, that every patient be regarded as an individual experiment in connexion with the administration of any cancerocidal agent, be it conventional or new.
All of this points to the human as the poorest of experimental animals, particularly the sick human, who is in no sense comparable to highly inbred strains of tumour-bearing animals on whom the new chemotherapeutic materials are tried initially. Thus, the first clinical trial of a substance which has shown promise in animal experimentation may prove very discouraging, for it must be used with patients who have failed to respond to conventional treatment. While most of them die, the study of their tissues at autopsy none the less offers an important means of evaluating the relative toxicity of the chemical on both neoplastic and normal cells, especially the blood-forming ones which are generally the most sensitive. The final phase, and the one requiring the greatest courage on the part of the investigator, is the testing of a promising cancerocidal agent on patients whose malignant disease is not overwhelming and who could probably be salvaged by conventional forms of treatment. Here, too, one is handicapped in his evaluation by the individual variants already recounted.
In an effort toward better understanding of the variables in humans, we have planned experiments which might disclose differences in host resistance to the tumour or in antigenic capacity of tumour tissue. By some such means it might prove possible to weight the results of clinical chemotherapy of cancer. It may be that the original nitrogen mustard is more effective against reticulum cell proliferation, and the other drugs against lymphoid cell proliferation.
When it comes to leukemia, it seems to me that the situation is a good deal clearer. There is undoubtedly a relationship between cytology and aggressiveness in chronic myeloid leukeemia. For instance, at one extreme there is the rare neutrophil leukaemia which goes smouldering on for perhaps ten years; in the middle there is the common chronic myeloid leukemia in which the average duration is perhaps three or four years, and this will usually terminate by a sudden outpouring of primitive myeloblasts.
There is also a clear-cut relationship between the response of the diseases to chemotherapeutic agents. For instance, chronic myeloid leukemia will respond by some degree of remission to almost all chemotherapeutic agents, but when it reaches the undifferentiated myeloblastic stage it only responds to 6-mercaptopurine. In chronic lymphatic leukiemia, the small cell type is generally admitted to run a more chronic course than the large cell type, although there are many exceptions. Finally in the acute leukiemias there is possibly some relation between cytological type and the response to chemotherapeutic agents. When there is general agreement that a case is one of myeloblastic or lymphoblastic leukiemia, there is a good chance that remission will occur with 6-mercaptopurine.
Remission is much less likely when it is one of those cases where nobody can agree on the exact nature of the cell and when one himatologist says it is a myeloblast, the next a lymphoblast, and the third a monoblast. That is to say, where the cells are completely undifferentiated, the chances of remission are far less good. Dr As a Southerner, I am particularly honoured to be asked to join this transatlantic conference. As our friends in England may remember, there was a bit of a strife in this country between the North and the South almost a century ago. We, in the South, did not really lose this war; we simply wore ourselves out winning battles. This conference is an excellent demonstration of the absence of provincialism or nationalism in medical science.
I was asked to discuss a topic on which there is no general agreement, no hard core of accepted facts-just opinions and the belief that if there were at hand a sound rationale for direction of research in the area of cancer chemotherapy, the whole world-wide effort would proceed in a more orderly, efficient, and rapid manner. Therefore, in the absence of any real over-all rationale for cancer chemotherapy, you must listen to some vague "semi-rationales", or something allied thereto. The biologic entities most generally associated with the cellular change resulting in cancer are genes and viruses. We know that both genes and viruses are nucleoprotein in nature and that the hereditary capacity of genes and viruses is contained in their nucleic acids. Thus, on a biochemical basis, cancer might appear to be a lesion in cellular nucleoprotein possibly resulting in a deleted or inactivated anabolic or catabolic enzyme responsible for some rate-controlling biochemical events. Here I have covered, or attempted to cover, a considerable ignorance with big words, but I have also tried to suggest a general concept which would allow some correlation between the somatic mutation and virus wtiology concepts (a virus-like particle is structurally well suited to causing genic changes in a cell).
Also the concept that gene changes are associated with cancer is well suited to the enzymedeletion concept which appeals to me. From the theoretical standpoint, it seems possible that rates of normal cell growth and division may be associated with a balance between certain anabolic and catabolic reactions, and deletion of catabolic catalysts (resulting from gene changes) might well shift the balance to a state of uncontrolled net synthesis and cell growth and division.
The agents which affect the course of leukiemia in animals and man, by and large, are agents which affect nucleotide and nucleic acid metabolism. X-radiation, a long-employed method for treatment of certain leukaemias and many other neoplasms, is an inhibitor of nucleic acid synthesis. Urethane, an antileukiemic agent discovered by Professor Haddow and his associates, affects glutamine and pyrimidine metabolism. Azaserine and DON, glutamine antagonists discovered by the Sloan-Kettering and the Parke, Davis groups, are inhibitors of purine nucleotide synthesis. A-methopterin, a useful temporary antileukxmic agent discovered by Dr. Farber and his group, blocks purine nucleotide and nucleic acid thymine synthesis. 6-mercaptopurine which came from collaborative work between the Burroughs Wellcome and Sloan-Kettering Institute laboratories and which causes temporary regressions in some cases of human leukemia, is almost certainly a purine nucleotide antagonist. Work in both Professor Haddow's laboratory and ours has shown that nitrogen mustards do indeed alkylate nucleic acids.
Thus, generally speaking, it appears that the antileukemic agents in use to-day probably act as inhibitors of nucleotide metabolism (affecting co-factor or nucleic acid synthesis) and, in turn, inhibit cell division. Therefore, one rational approach to cancer chemotherapy might be synthesis of a wide variety of analogues of the cellular intermediates en route to co-factor nucleic acid moieties. I can think of a great number of compounds that could be synthesized for trial on this semi-rational basis. Many of these, I am certain, are being made to-day in laboratories throughout the world. A second and perhaps more long-term rational approach is the direct search for the biochemical lesions responsible for cancer. If I were in possession of a genie with the power to grant one wish, I would, of course, ask the structure of a compound which would cure all cancer in man, but if this genie was a specialist who did not go along with applied research (a real fundamental genie who gave answers only to fundamental questions), then I would ask him what are the exact basic biochemical changes responsible for alteration of a normal cell to a cancer cell. I would publish this knowledge immediately (giving proper credit) and hope that such knowledge would make possible a direct scientific approach to the problem of (1) action which might be taken to prevent such chemical events in man, or (2) the design of drugs which would exploit these biochemical differences and provide the cytotoxic specificity required for curative cancer chemotherapeutic agents.
Still another rational approach to advancement of the status of cancer chemotherapy is that of unravelling the cause of failure of our presently known temporary antileukemic agents. Development of drug-resistant population of neoplastic cells is possibly one stumbling block en route to our goal. The basic knowledge required for some understanding and rational planning on the problem of drug resistance is being acquired more rapidly than many of us realize. It may be hoped that the possession of such knowledge will make it possible to devise means for coping with the development of drug resistance associated with present clinical chemotherapy of the leukaemias.
Finally, there are two general rational approaches to the advancement of cancer chemotherapy: (1) a search for the basic lesion of neoplasia on the biochemical level with hopes that such knowledge will allow for selection or design of drugs with greater usefulness, and (2) continued design and trial of drugs on the best hypotheses at hand hoping that better drugs will turn up and that study of their modes of selective action will lead us to the basic biochemical lesions of cancer. I personally encourage and endorse efforts in both directions.
Dr. Tocantins: The study of drug resistance and of the mechanism of action of the chemotherapy of leukemias and lymphomas leads almost into the heart of the mechanism of life. In attempting to control cancer we are going to learn a great deal about the mechanisms of life itself, underlining Dr. Ewing's statement that the study of cancer was virtually the study of life. Mr. Dickson Wright: Professor Haddow will now speak upon the prospects of cancer chemotherapy. Professor Haddow:
Cancer chemotherapy is obviously still in an embryonic stage. Nevertheless a good deal of progress has been made in the past ten years, resulting in agents which are clinically useful, even if only in a very limited sense. This progress still continues with experimental emphasis on agents with a far higher therapeutic index than those so far used. The present lines of work must be extended, and it would be quite wrong to discount the possibility of discovering new agents of greatly enhanced activity and wider application. But having said this, I am doubtful whether purely cytostatic agents or the antimetabolites, as we know them, have any permanent place in treatment. I have already made the point that the study of experimental chemotherapy should not be divorced from fundamental studies, and I believe the main importance of all these agents lies not in their practical application but in the light they shed on mechanisms of action, and on the nature of the cancer cell itself. As one example, many of the alkylating agents are capable of carcinogenic action in animals and much has been learned of the ways in which they could combine in the cell, with nucleoprotein perhaps in particular, to bring this about. The tentative conclusion, although not by any means proved, is that such agents bring about malignant change through a process of cytogenetical loss. The biochemical nature of the loss is not so far known. We have, however, speculated along the lines just referred to by Dr. Skipper whether it might involve the elimination of enzyme systems responsible for regulating the growth of the normal cell, so liberating the synthesis of growth-promoting substrates. This would account for the continuous and unregulated growth of the cancer cell. This idea is not only attractive but in very many ways reasonable. If it were to prove sound, we might perhaps envisage a new kind of chemotherapy in the future, in which the growthregulatory functions, apparently deficient in the cancer cell, would be re-imposed. This recalls certain types of substitution-therapy we already employ elsewhere, especially in pernicious anaemia, much of the underlying pathology of which is reminiscent of certain aspects of malignant change.
To summarize, progress will be made on present lines, we never know with what surprises, but the same agents will also be used to study the mechanism of carcinogenesis and to establish the essential biochemical differences between normal and cancer cells. This could lead to a new form of chemotherapy based upon rational understanding, and very different in kind from that which we employ to-day. Dr. Tocantins: We are very fortunate this afternoon in having two of the leading exponents of the chemotherapy of leukemia in this country, Dr. There are three classes of agents at present available for the treatment of acute Ieukaemia. First there are the folic acid antagonists discovered by Dr. Farber's group, of which Methotrexate, previously called amethopterin, is perhaps the best. Secondly, there are the purine antagonists exemplified by mercaptopurine, chloropurine and thioguanine. None of the latter is any better than 6-mercaptopurine. Thirdly we have the adrenal steroids. Of the last the prednisone type is preferable since there are less of the undesirable side-effects of sodium and water retention. The folic acid antagonists and purine antagonists require three to eight weeks to exert their beheficial effects, but the remissions are generally longer than with the more rapidly acting steroids. For that reason we believe that the folic acid antagonists and the purine antagonists should be the main chemotherapeutic agents, and that the steroids should be reserved for emergency situations such as fulminating disease or gross haemorrhagic tendency, where rapid action is essential, or for cases in which resistance to the antimetabolites has developed. In the acute leukoemias, signs and symptoms of meningeal infiltration occasionally develop. This may be treated successfully by intrathecal injections of Methotrexate or by radiation to the whole cranium. Beneficial effects have been achieved by intrathecal Methotrexate both in patients whose peripheral disease was resistant as well as in those whose disease was sensitive to Methotrexate.
Acute leukemia in children may respond to all three types of therapy and a high percentage of patients will respond to at least one.
With such a regime as I have outlined we have found 50% of our last 253 children with acute leukemia survived for just over twelve months as compared with the usual 50 % survival of four to five months before these specific modes of therapy were available.
Previously untreated adults rarely respond to the folic acid antagonist, but about 15-25% will respond to the purine antagonist and about the same response may be expected from the steroids. In patients who have responded at first to 6-mercaptopurine and have then developed resistance, Ellison showed that there is a 30 % remission rate with Methotrexate so that it is important not to abandon folic acid antagonists in the acute leukamias of adults. They should be tried after mercaptopurine has been tried. Since the percentage of adults responding to any therapy is small, the overall increase in survival time is not very significant, but in those in whom remissions are achieved, a median survival time of about twelve months can be expected.
In chronic granulocytic leuktemia, Myleran is the chemotherapeutic agent of choice.
How survivals will compare over a long term with those after X-ray therapy is impossible to state for certain at this time. Preliminary studies by Krakoff et al. suggest that chlorambucil will also produce remissions in this disease.
In chronic lymphocytic leukemia, chlorambucil is the drug of choice, but X-ray therapy to nodes and spleen is also excellent treatment. Preliminary studies by Galton and by our group have shown that Myleran can also produce remissions in this disease, but how it will compare with chlorambucil cannot at present be stated.
The adrenal steroids are of considerable value in controlling the hemolytic anaemia and thrombocytopenia associated with this form of leukemia, but again it is too early to assess the effects on survival time.
In the localized lymphomas we prefer localized radiation therapy. When the process is generalized, chemotherapy is indicated. For rapid effect in Hodgkin's disease, we prefer intravenous nitrogen mustard, or possibly intravenous T.E.M. (triethanomelamine). For maintenance therapy chlorambucil by mouth seems to be well tolerated and well absorbed. The adrenal steroids will produce regressions in lymphosarcoma and reticulum cell sarcoma, and are frequently beneficial in treating the hemolytic anemias associated occasionally with all the lymphomas. The effects of these forms of therapy on the overall median survival time of patients with lymphomas is not at present clear, but it is our clinical impression that in certain cases marked increase in expected survival time can be achieved. leukemias is intravenous trichlorethylamine hydrochloride, and that the newer preparations are not so good although perhaps a little more gentle with the patients in that they do not produce as much nausea. In the acute leukemias there are very few agents that can produce prolonged and beneficial effects. With the nucleotoxic agents and the antimetabolites that previous speakers have mentioned such as aminopterin, amethopterin and 6-mercaptopurine, we have only been getting approximately 30% remissions for periods up to twelve to eighteen months. It is easy to get toxic effects if you are not careful, and the subsequent relapses are not easy to treat.
Our best results have been obtained with the steroid hormones, particularly prednisolone, and by giving prednisolone in high dosage and for prolonged periods we do get approximately 40% remissions for much longer periods. The first patient I treated was in 1951, and she only required treatment for six months. She had two courses of treatment in that period, and for six years has been perfectly fit and well without any symptoms. The blood is normal, the marrow is normal. Clinically she is a perfectly well child, back at school and leading a normal life. We have tended to give up the anti-folic acid agents and concentrate on the steroids. It is interesting that children respond much better than adults in these acute leukemias with one exception-the acute monocytic leukemias appear to respond better in adults, some of whom we have been able to keep going for one to two years.
The chronic leukmmias do not benefit from the steroids nor from the antimetabolites, except that a few chronic myeloid leuklmias may respond to mercaptopurine. Both chronic myeloid and chronic lymphatic leuklmias respond extremely well and rapidly to intravenous trichlorethylamine hydrochloride. It may only be necessary to give two or three doses of 5-6 mg. intravenously, and large glands, the spleen and the liver will go down in a matter of a week or a fortnight. Of a series of 140 severe cases selected because they had large glands, spleens and livers, in the course of one to four weeks 94% lost their splenomegaly, and 91 % their enlarged glands, the white cells returning to normal. They needed subsequent similar short courses of treatment at intervals varying from three months to over two years. One or two of these patients whom I first treated during the war are still alive.
The chemotherapeutic agents that we give orally have also introduced interesting possibilities. Chronic myeloid leukemia responds very well to Myleran. One can ultimately reduce the dose in many cases to 2 mg. once a week, and with perhaps an occasional slight increase. Colcemid, (deacetyl-methyl-colchicine) acts similarly, but is not quite so easy to control. Chlorambucil has been disappointing in the myeloid leukemias.
T.E.M. is a very dangerous drug, and, although it may be efficient for a short time, aplastic anemia, thrombocytopenia, and agranulocytosis are frequent complications. I think T.E.M. should be removed from our armamentarium, particularly as we have better and safer therapeutic agents.
The chronic lymphatic leukamias do not usually respond to Myleran, Colcemid, T.E.M.,
and Urethane, but they may respond to chlorambucil or to the substance R 48. If the patient has suitable veins the quickest and best treatment is either intravenous nitrogen mustard or intramuscular thioTEPA. Hodgkin's disease reacts similarly, and I know of no treatment as good as intravenous trichlorethylamine hydrochloride given in small dosages.
In 80 cases of Hodgkin's disease, all selected because they had large glands that could be photographed and with large spleens, with doses of 6-30 mg. spread over two to three days, there was complete regression of the splenomegaly in 76% and partial regression in 16%, whereas in the lymphadenopathies 83% lost their large spleens and 9% showed regression. The survival time of these patients has been good, the longest to date being twelve years. None of these cases were of the mild type that often does not need treatment. In the other reticulosis, the results are not so good. Wilkinson said would I am sure be challenged by certain members of our panel. I would like to state that these proceedings are being broadcast and are being heard now in the National Cancer Institute in Bethesda, Maryland, and at the Walter Reed Army Medical Centre. We are even getting questions relayed to us from these two audiences.
The next few minutes will be dedicated to the questions from our panel to the British panel. The first question, which is being asked from Dr. Burchenal, is directed to Dr. Bodley Scott. Have you any experience with chlorambucil in the treatment of chronic granulocytic leukiemia or Myleran in chronic lymphocytic leukemia? Dr. Bodley Scott:
I have had no experience but I would suggest that the question be referred to Dr. Wiltshaw who I believe has some experience of Myleran in treating chronic lymphocytic leukemia.
Dr. Wiltshaw: Dr. Galton has treated 3 cases of chronic lymphatic leukemia with Myleran, and he felt that in these cases he got a definite drop in the white cell count, and a response which could be expected with any of the other drugs, the only disturbing feature was that one of the cases got what he thought was disproportionate platelet drop and one case developed purpura. Of these cases, 2 of them were treated with 4 to 6 mg. daily and 1 case was treated in the early days of Myleran with large doses, in five days she received 318 mg. This patient had no purpura and proceeded to a remission of about two years. We think it worth while to use this drug in chronic lymphatic leuklmia. We have 50% survival fourteen months after the beginning of treatment; this includes all children whether they died within an hour after admission, or whether they had treatment or not. 10% are still alive at two and a half years; a few are still alive at four to four and a half years. One child had an unbroken folic acid antagonist remission of eighty-eight months-seven years and four months-and died, I am unhappy to say, a few weeks ago with staphylococcus infection, ninety-eight months after the beginning of therapy.
It is not a question of which one of these agents is the best. In the course of treatment we need every one of them, and there is no question from our experience that folic acid antagonists may be given safely without the production of toxic effects and be productive of very long remissions. This is also the experience of Dr. Burchenal and many other people in this country. So that answer to the question is that all four of these agents, the corticosteroids, ACTH, folic acid antagonists and purine antagonists, have a very important place in the course of treatment of any given patient with acute leukwmia. What one should expect from super-voltage radiotherapy is perhaps that a greater dose can be given to tumours, particularly deep tumours, with less damage to the skin and to the surrounding tissues. Therefore super-voltage therapy has a limited usefulness in lymphomata, particularly where the main mass is in the mediastinum or in the vertebral column causing pressure on the cord. Radiotherapy is never more than symptomatic in the treatment of these diseases because the diseases are potentially generalized from the beginning. I do not believe we can expect very much more from greater super-voltage radiotherapy than we already have from present super-voltage radiotherapy. I can only speak of the effect of combination chemotherapy in experimental animals. I should like to make one brief statement on that point and then pass to Dr. Burchenal who has carried out combination chemotherapy in the clinic. I think that this is a theoretically very promising approach to the advancement of the status of cancer chemotherapy for two reasons. Theoretically, it is a good means for preventing the development of drug resistance, and also a method for obtaining sequential blockade in a series of chemical events which might result in potentiation. Certainly, unequivocal potentiation of the antileukoemic activity of drugs has been observed with combinations of drugs in experimental leukwmias and tumours.
Dr. Burchenal:
6-mercaptopurine and azaserine in mouse leukemia and in sarcoma 180 have a definite potentiating effect. For that reason the combination of 6-mercaptopurine and azaserine has been tried in children with acute leukemia. This study has been done by some 14 different co-operating groups and is still in progress. It appears that in a small percentage of patients the length of remission on 6-mercaptopurine can be prolonged by the addition of azaserine. I think that combination chemotherapy has a great future. All we need are some good compounds to use in combination.
Dr. Tocantins: We now have only about a minute or so to go, and there is one basic question that Dr. Skipper would like to direct to Professor Haddow. "Is enough effort being directed towards the discovery of biochemical differences between normal and neoplastic cells?" Professor Haddow:
I think that insufficient work is being done along these lines. But much more has been done during the past ten years than ever before. Of all the rational approaches, this is by far the most important, and in saying this I am thinking not only of biochemical differences but also of biophysical and immunological differences between normal and cancer cells. 
